⌕
Taysha Gene Therapies · TSHA · Nasdaq
Tenet 58 · Mixed
Compare
$4.00−1.48%At closeTenet 58 · Mixed
$4.00−0.06 (−1.48%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Taysha Gene Therapies (TSHA) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

12 figures withheld by our checks. Each blank figure names its reason.

Business engineChoppy: revenue is 37% below its peak, net margin −1115.3%. Worth your attention in FY25: Share count (+749.2%) and Capex step-up ($738.0K). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲17.3%
9.8
FY22→FY25CAGR +57.5%/yr
Net income ($M)▼22.1%
−109.0
FY21→FY25CAGR —
Free cash flow ($M)▼15.0%
−93.8
capex stepped upCAGR —
Diluted EPS▲5.6%
−0.34
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+749.2%

37.7mn → 319.7mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex step-up
$738.0K

▲97% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)9.8Revenue0.0COGS−86.4R&D−33.9SG&A−110.5Op income1.5Tax & other−109.0Net income

-1115¢ of every revenue dollar becomes profit.

Margin trend · direction beats level Operating Net
108530%sector median net margin ~3%FY21FY25

Net margin -1115.3% is below the sector median. This filer reports no gross profit line, so that margin is not drawn.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.7873, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
5.59.88.315.52.50.0▲17.3%+57.5% (22→25)
Cost of revenue
—0.00.00.00.00.0——
Gross profit
—A—A—A—A—A0.0——
Research & development
126.286.466.056.891.2131.9▲30.9%−10.0%
Selling, general & admin
43.833.929.030.037.441.3▲17.0%−4.9%
Total operating expenses
166.5120.399.887.9164.9173.3▲20.5%−8.7%
Operating incomefeeds ROC rank
−161.0−110.5−91.5−72.4−162.4−173.3▼20.8%—
Other income, net
5.01.52.2−39.1−3.6−1.3——
Pretax income
−156.0−109.0−89.3−111.6−166.0−174.5▼22.1%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−156.0−109.0−89.3−111.6−166.0−174.5▼22.1%—
Per share
Diluted EPSbuyback-sensitive
−0.43−0.34−0.36−0.96−3.78−4.64▲5.6%—
Diluted shares (mn)
406.11319.71250.13116.1243.9537.65▲27.8%+70.7%
Margins
Gross margin
—A—A—A—A—A———
Operating margin
−2935.4%−1130.6%−1097.6%−468.8%−6492.7%—▼33.1pp+5362.0pp
Net margin
−2844.6%−1115.3%−1071.6%−722.1%−6635.3%—▼43.6pp+5520.0pp
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
FY20 – FY20 · 1 more year
Unlock the full history →
1 more year of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-19 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Taysha Gene Therapies' revenue last fiscal year?

Taysha Gene Therapies reported revenue of $9.8M in fiscal 2025, up 17.3% from fiscal 2024.

What was Taysha Gene Therapies' net income?

Taysha Gene Therapies reported net income of −$109.0M in fiscal 2025, a net margin of −1115.3%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.